Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Ambrx, Inc.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03255070CT.gov A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | — | Completed | — | — | — |
NCT02512237CT.gov A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | — | Terminated | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| arx788 (this asset) | Ambrx, Inc. | P2 | CCC · 52 |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Eribulin Monomethanesulfonate | Fudan University | P4 | BB |
| Palbociclib | Eli Lilly and Company | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for arx788
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | B · 60 |
| HER2 Positive Breast Carcinoma | — | P2/3 | CCC · 54 |
| Angiosarcoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. arx788 in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/arx788-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →